These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3211990)

  • 21. Circadian phase dependent pharmacokinetics of disopyramide in mice.
    Bruguerolle B
    Chronobiol Int; 1984; 1(4):267-71. PubMed ID: 6600029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A rapid and sensitive liquid chromatography/tandem mass spectrometry assay for simultaneous quantitation of disopyramide and its major metabolite, mono-isopropyl-disopyramide, in rat plasma and its application to a pharmacokinetic study.
    Pham QK; Seo H; Ahn SH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Oct; 1096():154-159. PubMed ID: 30173081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Pike E; Lunde PK
    Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disopyramide kinetics in patients with acute myocardial infarction.
    Ilett KF; Madsen BW; Woods JD
    Clin Pharmacol Ther; 1979 Jul; 26(1):1-7. PubMed ID: 445953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study on transport of disopyramide into the intestinal lumen aimed at gastrointestinal dialysis by activated charcoal in rats.
    Arimori K; Nakano M
    J Pharm Pharmacol; 1989 Jul; 41(7):445-9. PubMed ID: 2570848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
    Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
    Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
    Aitio ML
    Br J Clin Pharmacol; 1981 Apr; 11(4):369-75. PubMed ID: 7259930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immediate- versus controlled-release disopyramide: importance of saturable binding.
    Davies RF; Siddoway LA; Shaw L; Barbey JT; Roden DM; Woosley RL
    Clin Pharmacol Ther; 1993 Jul; 54(1):16-22. PubMed ID: 8330460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the anticholinergic effects of two formulations of disopyramide in healthy volunteers.
    Longmore J; Berry JL; Szabadi E; Bradshaw CM
    Eur J Clin Pharmacol; 1990; 39(3):305-9. PubMed ID: 2257872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
    Upton RA; Williams RL
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability of disopyramide in normal volunteers using unbound concentration.
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of disopyramide in patients with chronic renal failure.
    Francois B; Mallein R; Rondelet J; Lussignol M
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.
    Takahashi H; Tamura A; Ogata H; Masuhara K
    J Chromatogr; 1990 Aug; 529(2):347-58. PubMed ID: 2229254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of phenytoin on serum disopyramide concentrations.
    Nightingale J; Nappi JM
    Clin Pharm; 1987 Jan; 6(1):46-50. PubMed ID: 3816106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo interaction of the enantiomers of disopyramide in human subjects.
    Giacomini KM; Nelson WL; Pershe RA; Valdivieso L; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):335-56. PubMed ID: 3772736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disopyramide pharmacokinetics in patients with acute myocardial infarction.
    Pentikäinen PJ; Huikuri H; Jounela AJ; Wilen G
    Eur J Clin Pharmacol; 1985; 28(1):45-51. PubMed ID: 3987785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disopyramide plasma levels in cardiac patients on maintenance therapy.
    Landmark K; Storstein L; Larsen A
    Acta Med Scand; 1979; 206(5):385-9. PubMed ID: 525439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias.
    Capparelli EV; DiPersio DM; Zhao H; Kluger J; Chow MS
    J Clin Pharmacol; 1988 Apr; 28(4):306-11. PubMed ID: 3392228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human pharmacokinetics and metabolism of disopyramide enantiomers.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.